Research Group for General Practice, Department of Public Health and Primary Health Care, University of Bergen, P.O. Box 7804, 5020, Bergen, Norway.
Eur J Clin Pharmacol. 2012 Mar;68(3):311-9. doi: 10.1007/s00228-011-1124-2. Epub 2011 Sep 18.
To examine (1) incidence rates for treatment with addictive anxiolytics and hypnotics in Norway, (2) the proportions initiated by general practitioners (GPs), psychiatrists, and other physicians, and (3) the course of the treatment among incident users during a 3.5 year follow-up period.
Data on all prescriptions of anxiolytics (ATC code N05B) and hypnotics (N05C) dispensed to the general population from 1 January 2004 to 31 August 2009 were extracted from the Norwegian Prescription Database and merged with data about GPs from the Norwegian Regular General Practitioner Scheme.
One-year incidence rates per 1,000 inhabitants were 18.2 for anxiolytics, 24.5 for hypnotics, and 35.4 for anxiolytics and hypnotics combined. GPs and psychiatrists initiated the treatment to 75.4 and 2.4%, respectively. Only 30.8% received short-term treatment as recommended. Long-term use (11.8%) and heavy use (1.4%) were most common for treatments initiated by a GP, but the risk both of long-term and of heavy use was highest for patients initially treated by a psychiatrist. The amount redeemed during the first quarter was the strongest predictor of long-term use and of heavy use. However, even during the quarter with highest drug consumption, 81.5% of the patients received <1 DDD/day.
This study indicates that physicians' prescribing strategy towards initial users is crucial in order to prevent inappropriate drug use. There is a need to implement relevant guidelines and systems for structured clinical audits in general practice.
考察(1)挪威治疗成瘾性抗焦虑药和催眠药的发病率,(2)由全科医生(GP)、精神科医生和其他医生开始治疗的比例,以及(3)在 3.5 年随访期间新使用者的治疗过程。
从挪威处方数据库中提取 2004 年 1 月 1 日至 2009 年 8 月 31 日期间向普通人群开出的所有抗焦虑药(ATC 代码 N05B)和催眠药(N05C)的处方数据,并与挪威常规全科医生计划中关于全科医生的数据合并。
每千名居民的一年发病率为 18.2 例抗焦虑药、24.5 例催眠药和 35.4 例抗焦虑药和催眠药联合用药。GP 和精神科医生开始治疗的比例分别为 75.4%和 2.4%。只有 30.8%的人接受了推荐的短期治疗。GP 开始治疗的患者最常见的是长期使用(11.8%)和重度使用(1.4%),但最初由精神科医生治疗的患者长期和重度使用的风险最高。第一个季度的赎回金额是长期使用和重度使用的最强预测因素。然而,即使在药物消费最高的季度,81.5%的患者接受的药物剂量<1 DDD/天。
本研究表明,医生对初始使用者的处方策略对于防止不当用药至关重要。需要在一般实践中实施相关指南和系统,以进行结构化的临床审核。